Wednesday, May 27, 2026
ADVT 
International

UK opens second ballot for Young Professional visa scheme for Indians

Darpan News Desk IANS, 25 Jul, 2023 11:42 AM
  • UK opens second ballot for Young Professional visa scheme for Indians

London, July 25 (IANS) The UK government has announced the opening of the second ballot of the Young Professional Scheme for Indian citizens between 18 to 30 years of age.

The ballot, which opened on Monday, will close at 1.30 p.m. on Thursday, the British High Commission announced in a tweet.

The scheme, formally launched this year, allows Indian citizens with a graduate or postgraduate qualification to live and work in the UK for up to two years.

It allows the candidate to enter the UK at any time while their visa is valid, and leave and come back at any time during their stay. T

here are 3,000 places available for the India Young Professionals Scheme visa in 2023.

While most places were given in the first ballot which opened in February, the remaining places will be given in the July ballot.

Successful candidates in the ballot need to apply for their visa by the deadline given in a subsequent invitation to apply, which is usually within a month's period.

Also, they must travel to the UK within six months of applying for their visa.

The application fee charges have been set at 259 pounds and additional costs involved is a 940-pound healthcare surcharge and proof that the applicant has 2,530 pounds in personal savings.

To be eligible for the Young Professionals Scheme visa one must be an Indian national or citizen between 18 and 30 years old and have 2,530 pounds in savings to support themselves in the UK.

Also applicants should not have children under the age of 18 living with them or who they are financially responsible for.

MORE International ARTICLES

FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

FDA approves first COVID-19 drug: antiviral remdesivir

Here we go again: Trump, Biden reprise debate duel

Here we go again: Trump, Biden reprise debate duel
Instead, they're bracing for another show of vintage Trump, one in which he'll seek to be heard even in spite of his muted microphone.

Here we go again: Trump, Biden reprise debate duel

Getting ready for the gong show: Trump v. Biden II

Getting ready for the gong show: Trump v. Biden II
It's the sequel to last month's debate horror show between Donald Trump and Joe Biden, an invective-laced 90 minutes that laid bare the depths to which political discourse can sink in an American election year.

Getting ready for the gong show: Trump v. Biden II

US overdose deaths appear to rise amid coronavirus pandemic

US overdose deaths appear to rise amid coronavirus pandemic
Davidson lost his job. He started staying home alone in his apartment near Georgetown, Kentucky — depressed and yearning for his recovery support group that had stopped gathering in person, said his cousin Melanie Wyatt.

US overdose deaths appear to rise amid coronavirus pandemic

Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer: Mid-November earliest it can seek virus vaccine OK
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer: Mid-November earliest it can seek virus vaccine OK

UN: Europe's pandemic restrictions are absolutely necessary

UN: Europe's pandemic restrictions are absolutely necessary
In a meda briefing on Thursday, Dr. Hans Kluge warned that even more drastic steps might be needed in such “unprecedented times.”

UN: Europe's pandemic restrictions are absolutely necessary